Vertex Pharmaceuticals
NEWS
Birmingham, Alabama resident Emily H. will be able to pursue her dream of studying elementary education ad Auburn University due in part to a $5,000 scholarship awarded by Vertex Pharmaceuticals.
The first quarter of 2018 for Vertex Pharmaceuticals was highlighted by the U.S. Food and Drug Administration’s February approval of Symdeko, a combination treatment for cystic fibrosis.
Every year for the last 32 years, Enrst & Young has awarded entrepreneurs in various categories, including Life Science, Consumer Products and Retail, Distribution and Manufacturing and other categories. The awards are given in June. The finalists have been announced. Here’s a look at some of the finalists and semi-finalists.
The difference between the salaries paid to top executives and the median income earned by rank and file employees has been a sore subject for many years and has served as a wedge political issue in recent elections.
It may not seem like it, but biotech stocks are actually up over the past year. The iShares Nasdaq Biotechnology ETF (IBB) is up about 4%--nothing to write home about, but hardly a disastrous performance.
Bluebird bio announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia (TDT).
Today, on this 11th World Rare Disease Day, life science companies, organization and activists have come together to raise awareness about these diseases and the needs of therapies for patients.
Vertex Pharmaceuticals announced that Reshma Kewalramani will be the new chief medical officer and executive vice president, Global Medicines Development and Medical Affairs
Vertex Pharmaceuticals announced it is starting its first Phase III trial of VX-659, a triple combination of the VX-659, tezacaftor and ivacaftor for cystic fibrosis.
JOBS
IN THE PRESS